Baxalta US Inc. has been honored by the 2015 Chicago Innovation Awards for HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], a treatment for adults with primary immunodeficiency (PI).
Recognized as a meaningful innovation in addressing unmet needs for patients with PI, HYQVIA is the only immunoglobulin treatment that offers a demonstrated safety and efficacy profile while delivering a full therapeutic dose via one needle in one infusion site, for most patients, up to once a month. HYQVIA is infused subcutaneously and can often be self-administered at home, giving patients a new level of control over their treatment.
PI includes a group of more than 200 diseases wherein part of the person’s immune system is missing or not functioning correctly.1 People with PI may be more likely to get recurring infections and may take longer to recover from them. Managing PI is a daily and lifelong challenge, and research shows that many desire treatment options that can meet their individual lifestyle needs.
“Patients are at the center of everything we do at Baxalta. Reducing the burden of disease and innovating to meet unmet needs is not only our business, but our passion,” said Jacopo Leonardi, executive vice president and president, Immunology, Baxalta. “We’re honored to receive this award for HYQVIA, which is a testament to the hard work and dedication of our team and their unwavering commitment to supporting PI patients worldwide.”
Chicago Innovation Award winners were announced at an event held at Chicago’s Harris Theater on Tuesday, October 27, with nearly 1,500 business and civic leaders attending. The Chicago Innovation Awards is the Chicago region’s foremost recognition of the most innovative new products or services brought to market or to public service each year.
Please see the Full Prescribing Information and Patient Product Information for HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], including Boxed Warning.
REFERENCES
1. Ballow M. Historical perspectives in the diagnosis and treatment of primary immune deficiencies. Clin Rev Allergy Immunol. 2014 Apr;46(2):101-3
Help employers find you! Check out all the jobs and post your resume.
Recognized as a meaningful innovation in addressing unmet needs for patients with PI, HYQVIA is the only immunoglobulin treatment that offers a demonstrated safety and efficacy profile while delivering a full therapeutic dose via one needle in one infusion site, for most patients, up to once a month. HYQVIA is infused subcutaneously and can often be self-administered at home, giving patients a new level of control over their treatment.
PI includes a group of more than 200 diseases wherein part of the person’s immune system is missing or not functioning correctly.1 People with PI may be more likely to get recurring infections and may take longer to recover from them. Managing PI is a daily and lifelong challenge, and research shows that many desire treatment options that can meet their individual lifestyle needs.
“Patients are at the center of everything we do at Baxalta. Reducing the burden of disease and innovating to meet unmet needs is not only our business, but our passion,” said Jacopo Leonardi, executive vice president and president, Immunology, Baxalta. “We’re honored to receive this award for HYQVIA, which is a testament to the hard work and dedication of our team and their unwavering commitment to supporting PI patients worldwide.”
Chicago Innovation Award winners were announced at an event held at Chicago’s Harris Theater on Tuesday, October 27, with nearly 1,500 business and civic leaders attending. The Chicago Innovation Awards is the Chicago region’s foremost recognition of the most innovative new products or services brought to market or to public service each year.
Please see the Full Prescribing Information and Patient Product Information for HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], including Boxed Warning.
REFERENCES
1. Ballow M. Historical perspectives in the diagnosis and treatment of primary immune deficiencies. Clin Rev Allergy Immunol. 2014 Apr;46(2):101-3
Help employers find you! Check out all the jobs and post your resume.
